Potential therapeutic agents against COVID-19: What we know so far

The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chih-Chia, Chen, Mei-Yu, Chang, Yuh-Lih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176266/
https://www.ncbi.nlm.nih.gov/pubmed/32243270
http://dx.doi.org/10.1097/JCMA.0000000000000318
_version_ 1783524989109010432
author Lu, Chih-Chia
Chen, Mei-Yu
Chang, Yuh-Lih
author_facet Lu, Chih-Chia
Chen, Mei-Yu
Chang, Yuh-Lih
author_sort Lu, Chih-Chia
collection PubMed
description The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
format Online
Article
Text
id pubmed-7176266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-71762662020-04-23 Potential therapeutic agents against COVID-19: What we know so far Lu, Chih-Chia Chen, Mei-Yu Chang, Yuh-Lih J Chin Med Assoc Mini Review The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19. Wolters Kluwer Health 2020-04-21 2020-04-10 /pmc/articles/PMC7176266/ /pubmed/32243270 http://dx.doi.org/10.1097/JCMA.0000000000000318 Text en Copyright © 2020, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Mini Review
Lu, Chih-Chia
Chen, Mei-Yu
Chang, Yuh-Lih
Potential therapeutic agents against COVID-19: What we know so far
title Potential therapeutic agents against COVID-19: What we know so far
title_full Potential therapeutic agents against COVID-19: What we know so far
title_fullStr Potential therapeutic agents against COVID-19: What we know so far
title_full_unstemmed Potential therapeutic agents against COVID-19: What we know so far
title_short Potential therapeutic agents against COVID-19: What we know so far
title_sort potential therapeutic agents against covid-19: what we know so far
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176266/
https://www.ncbi.nlm.nih.gov/pubmed/32243270
http://dx.doi.org/10.1097/JCMA.0000000000000318
work_keys_str_mv AT luchihchia potentialtherapeuticagentsagainstcovid19whatweknowsofar
AT chenmeiyu potentialtherapeuticagentsagainstcovid19whatweknowsofar
AT changyuhlih potentialtherapeuticagentsagainstcovid19whatweknowsofar

Ejemplares similares